SALT LAKE CITY , July 25, 2022 /PRNewswire/ -- ARUP Laboratories today announced that it has begun in-house testing for monkeypox. The Orthopoxvirus (includes monkeypox virus) by PCR test (test code 3005716) is a real-time polymerase chain reaction (RT-PCR) test to detect the DNA of orthopoxviruses, including monkeypox.

ARUP's New Monkeypox Test Can Be Performed on More Specimen Types on High-Throughput Instruments

ARUP's test is similar to the CDC assay that other laboratories have begun offering to address overflow testing in public health laboratories and to heighten the national response to monkeypox, a rare infection characterized by fever, head and muscle aches, swollen lymph nodes, and a rash that resembles pimples or blisters. The ARUP test differs from the CDC assay in that it has been validated for both dry-swab specimen collection and for collection using viral transport media. Specimens are easier to collect and transport when viral transport media can be used.

In addition, ARUP's laboratory-developed test has been validated for an automated specimen extraction method and can be performed on high-throughput instruments to optimize workflow efficiency, decrease turnaround times, and enable rapid scaling of testing capacity if needed.

"Since the initial outbreak of monkeypox in the United States , ARUP has actively participated with the CDC and other national reference laboratories in formulating an appropriate national response," said Tracy George , MD, ARUP president and chief scientific officer. "We are well prepared and deeply committed to support the needs of public health laboratories and our hospital and health system clients nationwide to help manage this outbreak."

ARUP's test will also be submitted for New York Department of Health approval. During this approval process, ARUP will continue to offer monkeypox testing to New York clients through a referral partner.

ARUP also continues to perform all medically relevant tests, with the exception of viral cultures, to help provide a differential diagnosis for individuals suspected or confirmed to have monkeypox.

For more information about monkeypox testing at ARUP, visit Frequently Asked Questions on aruplab.com, or the ARUP Consult Monkeypox topic. The latest CDC information about monkeypox is available here.

About ARUP Laboratories Founded in 1984, ARUP Laboratories is a leading national reference laboratory and a nonprofit enterprise of the University of Utah and its Department of Pathology. ARUP offers more than 3,000 tests and test combinations, ranging from routine screening tests to esoteric molecular and genetic assays. ARUP serves clients across the United States , including many of the nation's top university teaching hospitals and children's hospitals, as well as multihospital groups, major commercial laboratories, group purchasing organizations, military and other government facilities, and major clinics. In addition, ARUP is a worldwide leader in innovative laboratory research and development, led by the efforts of the ARUP Institute for Clinical and Experimental Pathology®. ARUP is ISO 15189 CAP accredited.

ARUP Media Contact Lisa Carricaburu , media@aruplab.com, 801-541-5041

View original content to download multimedia:https://www.prnewswire.com/news-releases/arups-new-monkeypox-test-can-be-performed-on-more-specimen-types-on-high-throughput-instruments-301592742.html

SIGA Technologies, maker of the only available monkeypox treatment, is working to ramp up manufacturing for broader global distribution.

We just can't get a break from COVID. While things were inching closer towards normalcy, cases are rising again thanks to the latest dominant variant BA.5, which experts say is the most contagious COVID strain yet. Although the virus affects everyone differently, there are symptoms to watch out for that indicate you've had COVID and Eat This, Not That! Health spoke with Dr. Mark Fischer, Regional Medical Director at International SOS who explains what to know about BA.5 and symptoms to watch out

Monkeypox has spread across multiple countries, including the U.S., where the Centers for Disease Control and Prevention (CDC) has confirmed almost 5,000 cases since May. While reminiscent of the beginning of the COVID-19 pandemic, this viral disease spreads differently. We all remember masking up, wearing gloves, and waiting in line to get into the grocery store in 2020, but will we have to do that again because of this virus?Experts at the CDC and others say monkeypox spreads mostly through cl

AstraZeneca Plc (NASDAQ: AZN) has removed a Moderna Inc (NASDAQ: MRNA)-partnered cardiovascular disease candidate from its phase 2 pipeline. The Moderna-partnered candidate is AZD8601, a therapy based on mRNA encoding vascular endothelial growth factor (VEGF-A). In EPICCURE Phase 2a trial, the investigators injected the mRNA directly into the myocardium of patients undergoing elective coronary artery bypass surgery. Related: AstraZeneca Q2 Highlights: Profits Fall, COVID-19 Vaccine Sales Dip, Li

The company had said it was in talks with the FDA about seeking early approval, but Wall Street analysts thought the agency would make it wait to apply.

A federal court ruling has dealt a blow to Bausch Health by appearing to clear the way for generic competition for the company’s drug Xifaxan. Bausch Health stock (ticker: BHC) plummeted more than 50% Thursday morning on the news, and trading of the shares was halted. In 2020, Bausch Health Ireland and Salix Pharmaceuticals sued Norwich Pharmaceuticals in 2020 for patent infringement, regarding Norwich’s plans to bring a generic version of Xifaxan to market before its patents had expired, according to a Bloomberg Law report.

July 26 marks the 32nd anniversary of the Americans with Disabilities Act (ADA) ― an important civil rights law that works to ensure all people with disabilities have the same rights and opportunit...

With growing concerns that the monkeypox outbreak could turn into another pandemic, local health offices have been flooded with requests for the monkeypox vaccine. According to the Centers for Disease Control and Prevention, there have been just 330 cases here in Georgia as of July 29.

AstraZeneca's Covid-19 antibody drug slashes the risk of new variants emerging, the company said, as Britain faces mounting pressure to follow other Western nations in ordering doses.

The Biden administration said it would spend $1.74 billion to buy 66 million doses of Moderna updated Covid-19 vaccine, as well as the option to purchase up to 234 million additional doses, as part of a fall booster campaign. The deal Friday, which follows an agreement to buy 105 million doses of updated vaccines from Pfizer and partner BioNTech SE is expected to give the federal government enough shots for a booster push as early as September. Under the latest deal, the U.S. government has the option to buy up to an additional 234 million doses from Moderna.

Is Merck stock a buy as reports suggest it could put up $40 billion to acquire Seagen? Is MRK stock a buy right now?

What will the coronavirus situation be like in classrooms this year? With vaccines available for kids ages 6 months and up, things might be a little different.

Story at a glance For the study, more than 501,000 people with an average age of 56 from a U.K database filled out questionnaires asking how often they participated in various physical activities, household and job-related tasks and mental activities, like social visits. Participants reported their family history for dementia to help researchers narrow down…

CHICAGO (Reuters) -People at high risk of severe disease who have yet to get a second COVID-19 booster should not wait for next-generation, Omicron-targeted vaccines expected in the fall, five vaccine experts told Reuters. In many countries, including the United States, the BA.5 Omicron subvariant of the virus is surging, but current vaccines continue to offer protection against hospitalization for severe disease and death. And, as the virus evolves, it is not known what version will be widely circulating in the fall or whether new vaccines - expected to target BA.4/5 in the United States and BA.1 in Europe - will be a good match.

Dementia is a brain disorder that affects an estimated 55 million people worldwide according to the World Health Organization. The condition is becoming more common and while age is a leading risk factor, people under 65 can also have dementia, which causes memory loss, mood changes, getting lost in familiar places and more. Being aware of other risk factors like lack of sleep, poor diet, social isolation and not enough exercise can make a difference, but so does knowing your blood type, accordi

It's make-or-break time for Neurocrine Biosciences' essential tremors treatment, analysts say, as NBIX stock trends sideways.

Combined with 105 million doses the government already agreed to buy from Pfizer Inc and partner BioNTech SE for $3.2 billion, the latest deal puts the U.S. booster dose supply at about 171 million shots. COVID-19 infections in the United States have been on the rise as the BA.4 and BA.5 subvariants of the Omicron variant have spread to account for more than 90% of U.S. infections, according the U.S. Centers for Disease Control and Prevention. These subvariants have significant mutations from the earliest versions of Omicron and protection from vaccines wanes over time.

Is Pfizer stock a sell after Wall Street reduced its expectations for 2022 sales and profit? Is PFE stock a sell right now?

San Francisco Mayor London Breed declares a state of emergency Thursday over monkeypox outbreak.

The highly contagious BA.5 subvariant is causing a nationwide spike in cases, and experts believe the numbers might actually be higher thanks to at-home testing. But even without accurate data, there is no doubt a surge is happening. "You don't have to count every raindrop to know it's raining," says Dr. Joseph Kanter, Louisiana's state health officer and medical director. "And it's pouring right now." Here are five signs of BA.5 that are easy to miss, according to experts. Read on—and to ensure